摘要
高血压是最常见的心血管疾病,存在心血管疾病最常见的危险因素,并且是全世界引起死亡的主要原因。尽管有大量的抗高血压药物存在,但是大多数病人的血压仍旧得不到最佳控制,并且存在心血管并发症的高风险。目前治疗方法的局限性已经促进新一代抗不同作用机制高血压剂的研究与开发;它们可以使血压得到更好的控制,对器官损伤有更好的保护作用,较好的耐受性,且对心血管疾病有更有效的预防。然而,原发性高血压是一种多因素、多基因疾病,这就意味着多种机制或多或少地有助于增加血压。多重而复杂的细胞信号通路可以调节血管平滑肌细胞的收缩和增长,对于其认识的研究进展包括血管紧张力的调节和高血压诱导的终末器官损伤,为新的药物作用靶点的识别提供了有价值的见解。本文对于处在研发中的新的抗高血压药物的作用机制及与传统药物相比可能的优势进行了综述。
关键词: 抗高血压的,钙和钾通道阻断剂,高血压,基因,肾素-血管紧张素-醛固酮系统抑制剂,血管活性肽酶抑制剂
Current Medicinal Chemistry
Title:New Antihypertensive Drugs Under Development
Volume: 22 Issue: 3
Author(s): J. Tamargo, J. Duarte and L.M. Ruilope
Affiliation:
关键词: 抗高血压的,钙和钾通道阻断剂,高血压,基因,肾素-血管紧张素-醛固酮系统抑制剂,血管活性肽酶抑制剂
摘要: Hypertension is the most common cardiovascular disease and remains the most prevalent risk factor for cardiovascular diseases and a major cause of death worldwide. Despite the large number of antihypertensive drugs available, in the majority of patients blood pressure still remains not optimally controlled and persists at high risk of cardiovascular complications. The limitations of current therapies have stimulated the research and development of new classes of antihypertensive agents, with different mechanisms of action, that provide a better blood pressure control, greater protection against organ damage, better tolerability and more effective prevention of cardiovascular diseases. However, essential hypertension is a multifactorial and multigenic disorder, which means that various mechanisms contribute to a greater or lesser extent to increase BP. Recent advances in the understanding of the multiple and complex cellular signalling pathways that modulate vascular smooth muscle cell contraction and growth involved in the regulation of vascular tone and in hypertension-induced end-organ damage have provided valuable insight in identifying new therapeutic targets. This article reviews new antihypertensive drugs under development, focusing on their mechanisms of action and possible advantages compared with traditional drugs.
Export Options
About this article
Cite this article as:
Tamargo J., Duarte J. and Ruilope L.M., New Antihypertensive Drugs Under Development, Current Medicinal Chemistry 2015; 22 (3) . https://dx.doi.org/10.2174/0929867321666141106113018
DOI https://dx.doi.org/10.2174/0929867321666141106113018 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Aortic Stenosis: A Review
Current Hypertension Reviews UHPLC Quantitation Method for New Thiazolidinedione LPSF/GQ-02 and In Vitro/In Vivo Kinetic Studies
Drug Metabolism Letters Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]
Current Pharmaceutical Design Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Patent Selections:
Recent Patents on Biotechnology Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Optimizing the Management of Uncontrolled/Resistant Hypertension. The Importance of Sleep Apnoea Syndrome
Current Vascular Pharmacology Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Cardiovascular Implantable Electronic Device Infections: Risk Scoring and Role of Antibiotic Envelope in Prevention
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Amniotic Fluid Embolism: Review
Current Pharmaceutical Biotechnology Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews